Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 12/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6608146 | 1.00 | GHSR (0.47) | GHSRACENR1H2PRMT5WDR77 | |
| SCHEMBL18066415 | 0.88 | ACE (0.56) | GHSRACE | |
| SCHEMBL29560869 | 0.88 | ACE (0.56) | GHSRACE | |
| SCHEMBL605316 | 0.88 | ACE (0.56) | GHSRACE | |
| SCHEMBL14744581 | 0.88 | ACE (0.56) | GHSRACE | |
| SCHEMBL30310636 | 0.88 | ACE (0.56) | GHSRACE | |
| SCHEMBL6608138 | 0.87 | GHSR (0.46) | GHSRACENR1H2PRMT5WDR77 | |
| SCHEMBL6251794 | 0.87 | MEN1 (0.44) | GHSRACENR1H2PRMT5WDR77 | |
| SCHEMBL25142645 | 0.86 | GHSR (0.47) | GHSRACE | |
| SCHEMBL7702856 | 0.85 | ACE (0.46) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802934-B2 | Process for the synthesis of (R)-praziquantel | TONGLI BIOMEDICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9802934-B2 | Process for the synthesis of (R)-praziquantel | TONGLI BIOMEDICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9802934-B2 | Process for the synthesis of (R)-praziquantel | TONGLI BIOMEDICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | COASY, CYP3A4, CYP4B1 | GHSR 4426/4885ACE 456/4885NR1H2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.